Global PDE Inhibitors Market to Extend Generously During the Upcoming years
Global PDE Inhibitors Market Introduction
Phosphodiesterase (PDE) inhibitors are therapeutic agents that target PDE isoenzymes and hinder the metabolism of the secondary messengers (cyclic adenosine monophosphate, cyclic guanosine monophosphate) therefore, prolonging the biological effect determined by the type of cell involved. Selective and non-selective PDE inhibitors are being discovered as possible treatments for a variety of indications such as Alzheimer’s disease, chronic obstructive pulmonary disease (COPD), and other ailments. Phosphodiesterase super family is complex, large and represents 11 gene families from phosphodiesterase 1 to phosphodiesterase 11. Each of the phosphodiesterase families contains one or four genes. The phosphodiesterase are found in plasma membranes, cytosol, nuclear membranes, endoplasmic reticulum, and cytoskeleton.
Global PDE Inhibitors Market: Competitive Landscape
Pfizer, Inc.
Founded in 1849, Pfizer, Inc. is based in New York, U.S. It is a global pharmaceutical company that develops, manufactures, and markets prescription medicines in 11 therapeutic segments including cardiovascular, oncology, neuroscience, pain, and infectious diseases. The company offers a wide range of medicines and vaccines as well as consumer health care products for the prevention and treatment of infectious and chronic diseases for all age groups. Pfizer holds the leading position in the erectile dysfunction with its brand Viagra.
Need an Overview of the Report on PDE Inhibitors Market? Ask for the Brochure here
Eli Lilly and Company
Established in 1876, Eli Lilly and Company is located in Indianapolis, Indiana, U.S. It is a multinational pharmaceuticals organization, operating in more than 160 countries, with direct presence in 27 of them. The company primarily operates through three business segments: Pharmaceuticals, Animal Health, and Health Care Management Services. In the U.S., Eli Lilly and Company distributes human pharmaceutical products, principally through independent wholesale distributors, directly to pharmacies. Its human pharmaceutical products compete globally with products of many other companies in highly competitive markets.
Bayer AG
Incorporated in 1863, Bayer is based in Leverkusen, Germany. It is a life sciences company, operating in pharmaceutical, consumer health, animal health, and agriculture domains with 150 years of history and core competences in the areas of health care and agriculture. Bayer is a group of 241 consolidated companies located in 79 countries across the world. Its consumer health segment maintains a global network of research & development facilities, with sites in the U.S., France, Germany, and China.
GlaxoSmithKline Plc
Founded in 2000, GlaxoSmithKline is based in Brentford, U.K. It is a global health care company, which is concentrated on three key business divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company has a product portfolio of established and innovative medicines. It has expertise in respiratory diseases, HIV, oncology, immune-inflammatory diseases, and rare diseases. GSK has worldwide presence in more than 150 countries, with 33% of its offices and centers in emerging markets.
Global PDE Inhibitors Market: Dynamics
Increase in Prevalence of Erectile Dysfunction to Drive PDE Inhibitors Market
The key factor driving the PDE inhibitors market is the increasing prevalence of erectile dysfunction. The etiology of erectile dysfunction can be ascribed to multiple factors, such as prostate cancer, hypertension, obesity, testosterone deficiency, diabetes mellitus, and hyperlipidemia. Furthermore, the consumption of certain substance abuse and medications can lead to erectile dysfunction. As most of the causes are related to lifestyle changes, the prevalence of erectile dysfunction is increasing globally. According to the World Health Organization (WHO), about 150 million people have been affected by erectile dysfunction and this is projected to reach 230 million by 2025. It is a common medical condition affecting about 15% of men each year.
Stuck in a Neck-to-Neck Competition with other Brands? Request a Custom Report on “PDE Inhibitors Market” here
Increasing Burden of Chronic Diseases Expected to Fuel PDE Inhibitors Market
Chronic diseases such as stroke, chronic obstructive pulmonary disease, heart diseases, pre-diabetes, and diabetes are the leading causes of death. These diseases contribute to a considerable portion of annual health care expenditure. Increase in health care cost related to chronic diseases is expected to result in increased adoption of the PDE4 and PDE5 inhibitors. Therefore, an increase in the health related concerns and economic burden of these diseases is likely to increase the demand for PDE inhibitors which, in turn, is likely to promote the global PDE inhibitors market during the forecast period.
Pre Book Full Report Now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=71364<ype=S